Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
As a result, there is currently no data available to assess the clinical implications of GLP-1 RA use in this patient population
Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space
Shes written for The New York Times, The Cut, InStyle, etc., and been a contributing editor at Cosmo and Marie Claire.
Cannon, MD, Contributor Disclaimer: As a service to our readers, Harvard Health Publishing provides access to our library of archived content
